المؤلفون: Noorani A; MRC Cancer Unit, University of Cambridge, Cambridge, UK., Li X; MRC Cancer Unit, University of Cambridge, Cambridge, UK., Goddard M; Department of Histopathology, Papworth Hospital NHS Trust, Cambridge, UK., Crawte J; MRC Cancer Unit, University of Cambridge, Cambridge, UK., Alexandrov LB; Cellular and Molecular Medicine, University of California, San Diego, San Diego, CA, USA., Secrier M; Cancer Research UK Cambridge Research Institute, Cambridge, UK., Eldridge MD; Cancer Research UK Cambridge Research Institute, Cambridge, UK., Bower L; Cancer Research UK Cambridge Research Institute, Cambridge, UK., Weaver J; MRC Cancer Unit, University of Cambridge, Cambridge, UK., Lao-Sirieix P; MRC Cancer Unit, University of Cambridge, Cambridge, UK., Martincorena I; Wellcome Trust Sanger Institute, Cambridge, UK., Debiram-Beecham I; MRC Cancer Unit, University of Cambridge, Cambridge, UK., Grehan N; MRC Cancer Unit, University of Cambridge, Cambridge, UK., MacRae S; MRC Cancer Unit, University of Cambridge, Cambridge, UK., Malhotra S; Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Miremadi A; Department of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Thomas T; Arthur Rank Hospice Charity, Cambridge, UK., Galbraith S; Department of Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Petersen L; Arthur Rank Hospice Charity, Cambridge, UK., Preston SD; Department of Histopathology, Papworth Hospital NHS Trust, Cambridge, UK., Gilligan D; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Hindmarsh A; Cambridge Oesophago-Gastric Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Hardwick RH; Cambridge Oesophago-Gastric Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Stratton MR; Wellcome Trust Sanger Institute, Cambridge, UK., Wedge DC; Big Data Institute, University of Oxford, Oxford, UK. david.wedge@bdi.ox.ac.uk.; Oxford NIHR Biomedical Research Centre, Oxford, UK. david.wedge@bdi.ox.ac.uk., Fitzgerald RC; MRC Cancer Unit, University of Cambridge, Cambridge, UK. rcf29@mrc-cu.cam.ac.uk.

المصدر: Nature genetics [Nat Genet] 2020 Jan; Vol. 52 (1), pp. 74-83. Date of Electronic Publication: 2020 Jan 06.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Pub. Co Country of Publication: United States NLM ID: 9216904 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-1718 (Electronic) Linking ISSN: 10614036 NLM ISO Abbreviation: Nat Genet Subsets: MEDLINE

مواضيع طبية MeSH: Clonal Evolution* , Models, Statistical*, Adenocarcinoma/*secondary , Esophageal Neoplasms/*pathology , Genomics/*methods, Adenocarcinoma/genetics ; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Child ; Esophageal Neoplasms/genetics ; Esophageal Neoplasms/secondary ; Humans ; Male ; Middle Aged ; Phylogeny ; Whole Genome Sequencing ; Young Adult

SCR Disease Name: Adenocarcinoma Of Esophagus

المؤلفون: Baselga J; Vall d'Hebron University Hospital, Barcelona, Spain. jbaselga@vhebron.net, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG, Makhson A, Tjulandin S, Ludwig H, Verrill M, Ciruelos E, Egyhazi S, Xu LA, Zerba KE, Lee H, Clark E, Galbraith S

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2009 Feb 01; Vol. 27 (4), pp. 526-34. Date of Electronic Publication: 2008 Dec 15.

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Adenocarcinoma/*drug therapy , Antineoplastic Agents/*therapeutic use , Breast Neoplasms/*drug therapy , Epothilones/*therapeutic use, Adenocarcinoma/genetics ; Adenocarcinoma/pathology ; Adenocarcinoma/surgery ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Breast Neoplasms/surgery ; Drug Resistance, Neoplasm/genetics ; Epothilones/administration & dosage ; Epothilones/adverse effects ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Lymph Nodes/pathology ; Neoadjuvant Therapy ; Predictive Value of Tests ; RNA, Messenger/analysis ; Receptors, Estrogen/analysis

المؤلفون: Luo FR; Pharmaceutical Research Institute, Clinical Discovery, Bristol-Myers Squibb Company, Pennington, NJ 08534, USA., Barrett YC, Yang Z, Camuso A, McGlinchey K, Wen ML, Smykla R, Fager K, Wild R, Palme H, Galbraith S, Blackwood-Chirchir A, Lee FY

المصدر: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2008 Nov; Vol. 62 (6), pp. 1065-74. Date of Electronic Publication: 2008 Feb 27.

نوع المنشور: Journal Article; Validation Study

بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Adenocarcinoma/*pathology , Antineoplastic Agents/*pharmacology , Drug Monitoring/*methods , Neoplasm Proteins/*antagonists & inhibitors , Prostatic Neoplasms/*pathology , Protein Kinase Inhibitors/*pharmacology , Pyrimidines/*pharmacology , Thiazoles/*pharmacology , src-Family Kinases/*analysis, Adenocarcinoma/chemistry ; Adenocarcinoma/drug therapy ; Animals ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/pharmacokinetics ; Antineoplastic Agents/therapeutic use ; Biomarkers ; Cell Division/drug effects ; Dasatinib ; Female ; Humans ; Leukocytes, Mononuclear/chemistry ; Leukocytes, Mononuclear/drug effects ; Male ; Mice ; Mice, Nude ; Neoplasm Proteins/analysis ; Neoplasm Proteins/blood ; Phosphoproteins/antagonists & inhibitors ; Phosphorylation ; Prostatic Neoplasms/chemistry ; Prostatic Neoplasms/drug therapy ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/pharmacokinetics ; Protein Kinase Inhibitors/therapeutic use ; Pyrimidines/administration & dosage ; Pyrimidines/pharmacokinetics ; Pyrimidines/therapeutic use ; Specific Pathogen-Free Organisms ; Substrate Specificity ; Thiazoles/administration & dosage ; Thiazoles/pharmacokinetics ; Thiazoles/therapeutic use ; Xenograft Model Antitumor Assays ; src-Family Kinases/antagonists & inhibitors ; src-Family Kinases/blood

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.